BMJ Open

# Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Hanni Lin ,[1] Jing Han,[2] Ping Jiang,[1] Zhangbin Yu,[3] Ping Zhou,[4] Hong Tang,[5] Lu Ding,[3] Jiebo Liu[1]

**To cite:** Lin H, Han J, Jiang P, *et al*. Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study. *BMJ Open* 2024;**14**:e081670. doi:10.1136/bmjopen-2023-081670

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2023-081670 ).

HL and JH contributed equally.

Received 03 November 2023
Accepted 10 May 2024



For numbered affiliations see end of article.

**Correspondence to**
Dr Jiebo Liu;
446107008@qq.com

## ABSTRACT

**Introduction** Preterm birth complications and neonatal asphyxia are the leading causes of neonatal mortality worldwide. Surviving preterm and asphyxiated newborns can develop neurological sequelae; therefore, timely and appropriate neonatal resuscitation is important to decrease neonatal mortality and disability rates. There are very few systematic studies on neonatal resuscitation in China, and its prognosis remains unclear. We established an online registry for neonatal resuscitation in Shenzhen based on Utstein's model and designed a prospective, multicentre, open, observational cohort study to address many of the limitations of existing studies. The aim of this study is to explore the implementation and management, risk factors and outcomes of neonatal resuscitation in Shenzhen.

**Methods and analysis** This prospective, multicentre, open, observational cohort study will be conducted between January 2024 and December 2026 and will include >1500 newborns resuscitated at birth by positive pressure ventilation at five hospitals in Shenzhen, located in the south-central coastal area of Guangdong province, China. Maternal and infant information, resuscitation information, hospitalisation information and follow-up information will be collected. Maternal and infant information, resuscitation information and hospitalisation information will be collected from the clinical records of the patients. Follow-up information will include the results of follow-up examinations and outcomes, which will be recorded using the WeChat applet 'Resuscitation Follow-up'. These data will be provided by the neonatal guardians through the applet on their mobile phones. This study will provide a more comprehensive understanding of the implementation and management, risk factors and outcomes of neonatal resuscitation in Shenzhen; the findings will ultimately contribute to the reduction of neonatal mortality and disability rates in Shenzhen.

**Ethics and dissemination** Our protocol has been approved by the Medical Ethics Committee of Shenzhen Luohu People's Hospital (2023-LHQRMYY-KYLL-048). We will present the study results at academic conferences and peer-reviewed paediatrics journals.

**Trial registration number** ChiCTR2300077368.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ This prospective cohort study will establish a multicentre online registry of cases involving neonatal resuscitation for efficient data management.
⇒ The study will conduct follow-up for newborns resuscitated at birth for up to 2 years.
⇒ The study will comprehensively evaluate various aspects of the prognosis of neonates resuscitated at birth, including survival, recent major illness and long-term neurodevelopmental outcomes.
⇒ The study will investigate the implementation of resuscitation measures in neonates in an actual clinical setting.
⇒ Because this is an observational study, loss to follow-up will be inevitable.

## INTRODUCTION

Globally, approximately 2.44 million newborns die each year, 36.1% die of preterm birth complications and 23.9% die of birth asphyxia.[1] In China, preterm birth complications and delivery-related complications (birth asphyxia/trauma) rank first and second, respectively, among the leading causes of neonatal deaths.[2] Preterm neonates often have poor respiratory ability at birth and are unable to establish spontaneous breathing.[3] Moreover, survivors of preterm birth carry a high risk of neurological and developmental disabilities.[4] Neonatal asphyxia is caused by various factors that prevent neonates from establishing spontaneous respiration at birth,[5 6] and up to 25% survivors remain with permanent neurological deficits.[7] According to the WHO, many of the causes of neonatal mortality can be avoided by simple, practical and inexpensive techniques such as neonatal resuscitation.[8]

Following the establishment of the neonatal resuscitation programme by the American Academy of Pediatrics and the American Heart Association in 1987, guidelines for neonatal

resuscitation were developed and have been revised every 5 years on the basis of evidence-based medicine.[9] Clinical research in the field of neonatal resuscitation has evolved rapidly in recent decades.[10] Approximately 10% of newborns receive resuscitation for successful transition at birth.[11] With the development of perinatal medicine and the continuous promotion of neonatal resuscitation training programmes, the incidence of neonatal asphyxia in China has decreased from 6.23% in 2003 to 1.67% in 2014 and the morbidity and mortality rates have decreased from 7.55% to 1.39%.[12] Correct and standardised resuscitation measures can effectively decrease neonatal mortality and disability rates.

Many countries have realised the importance of neonatal resuscitation. The American Heart Association has established the Get with the Guidelines-Resuscitation Registry, the only national registry for inpatient cardiac arrest in North America; it is a prospective, quality-improvement registry of in-hospital cardiac arrest and resuscitation data, including studies of the characteristics and outcomes of neonates who survived cardiopulmonary resuscitation in the delivery room.[13–15] Furthermore, the National Institute of Child Health and Human Development (NICHD) Global Network for Women's and Children's Health initiated and registered interventional studies of neonatal resuscitation, which concluded that the perinatal mortality rate was decreased following enhanced training of birth attendants.[16 17]

In China, there are very few systematic studies on neonatal resuscitation. A retrospective study reported the short-term outcomes of delivery room resuscitation for very preterm and very low birth weight infants in 33 neonatal intensive care units (NICUs) in five provinces and cities in North China, although it did not provide information regarding post-discharge follow-up and outcomes of the infants.[18] Another retrospective study published in 2021 reported the clinical features of preterm infants with a birth weight of <1500 g who received resuscitation of different intensities in NICUs of 20 hospitals in Jiangsu province,[19] while yet another retrospective study published in 2023 reported the correlation between the intensity of delivery room resuscitation of preterm infants with a gestational age (GA) of $24^{+0}$–$31^{+6}$ weeks and their short-term outcomes from the Chinese Neonatal Network[20]; however, both these studies provided incomplete information for some cases.

Our study group established an online registry for neonatal resuscitation in Shenzhen on the basis of Utstein's model[11] and designed a prospective, multicentre, open, observational cohort study to address many of the limitations of existing studies. Here we describe the protocol for this study.

The primary objective of the study will be to investigate the comprehensive prognosis of newborns resuscitated at birth in Shenzhen.

The secondary objective will be to provide baseline information for improvement of the quality of neonatal resuscitation, enhancement of the resuscitation skills of neonatologists and achievement of a further decrease in neonatal mortality and disability rates in Shenzhen.

## METHODS AND ANALYSIS

### Study design

This multicentre, prospective, open, observational cohort study will be conducted from January 2024 to December 2026. More than 1500 newborns requiring resuscitation at birth by positive pressure ventilation (PPV) will be recruited from five hospitals in Shenzhen, located in the south-central coastal area of Guangdong province, China. All enrolled newborns will be followed-up to 2 years. The proposal has been approved by the medical ethics committees of the initiating hospital, and the other four hospitals have signed the multicentre collaboration agreements. Each hospital will be required to resuscitate the infant according to China neonatal resuscitation guideline (revised in 2021).[8] The protocol has been drafted in accordance with the Standardised Protocol Items: Recommendations for Observational Studies statement (online supplemental file 1).

Shenzhen Luohu People's Hospital, which is the affiliation of the promoter (JL) and primary investigator (HL), designed and initiated this study. Shenzhen People's Hospital is the coordinating hospital and the affiliation of the coordinators (LD and ZY). Several data recorders (neonatologists) and a data checker (neonatologist) have been appointed at each participating hospital. This is an open study, and we will welcome more eligible hospitals to participate. The flowchart of the study process is shown in online supplemental file 2.

### Patient and public involvement

The guardians of newborns and the public did not participate in the study design. The newborns will participate in the recruitment stage, and participation is entirely voluntary. WeChat groups will be established and guardians will be invited to join. The study results will be disseminated to guardians and the public by means of health brochures and academic conferences.

### Participants

Five hospitals in Shenzhen have formed a collaborative group for this multicentre study. Basic information about each hospital is shown in table 1. All newborns born and requiring resuscitation at birth by PPV in these hospitals between 1 January 2024 and 31 December 2026 will be included. Clinical practice of newborns will not be affected by their guardian's refusal to participate or withdrawal from the study.

### Informed consent

This study follows the Declaration of Helsinki, and written informed consent will be obtained from the guardians of all included newborns.

### Criteria

Inclusion criteria are as follows:

Table 1 Basic information and responsibilities for the five participating hospitals

| Hospital name | Responsibility | Number of infants delivered in 2022 |
|---|---|---|
| Shenzhen Luohu People's Hospital | Initiating hospital | 2079 |
| Shenzhen People's Hospital | Coordinating hospital | 5400 |
| Shenzhen Yantian District People's Hospital (Group) | Participating hospital | 1363 |
| Shenzhen Baoan Women's and Children's Hospital | Participating hospital | 18107 |
| Longgang District Maternity & Child Healthcare Hospital of Shenzhen City | Participating hospital | 12424 |

Newborn resuscitated at birth by PPV.

Informed consent has been obtained.

Exclusion criteria are as follows:

Severe congenital anomalies (eg, tetralogy of Fallot, complete transposition of the great arteries) and inherited metabolic disorders.

Forgo for resuscitation.

Less than one follow-up examination.

Refusal to consent.

## Standardisation of variable definitions

GA: GA is the number of completed weeks of gestation at birth.[21]

Corrected age: For each preterm infant, the corrected age is calculated by subtracting the number of weeks of preterm birth (40 weeks minus the actual week of gestation) from the calendar age at birth.[22]

Small for GA (SGA): SGA is defined as birth weight <10th percentile according to the Chinese neonatal birth weight values.[23]

Legal holidays: These are holidays uniformly stipulated by Chinese laws as breaks for celebrations and holidays, New Year's Day, Spring Festival, Qingming, Labour Day, Dragon Boat Festival, Mid-Autumn Festival, National Day, Women's Day, Youth Day, Children's Day and Army Day.

Assisted reproductive technology (ART): ART involves the use of hormones to downregulate pituitary function and stimulate the production of multiple oocytes, the manipulation of oocytes and sperm for in vitro fertilisation and intracytoplasmic monozoosperm injection procedures in vitro and cultivation of pre-implantation embryos in media and incubators prior to transfer to the uterus.[24]

Full course of antenatal steroids: This is defined as a course of four consecutive intramuscular injections of dexamethasone administered by the mother prior to delivery.

Antenatal steroid exposure: This is defined as less than four intramuscular injections of dexamethasone administered by the mother prior to delivery.

Prolongation of the second stage of labour: Without intrathecal analgesia, the second stage of labour exceeds 3 hours for primigravid women and 2 hours for transient women. If intrathecal analgesia is administered, the second stage of labour exceeds 4 hours for primigravid women and 3 hours for transient women.[25]

Mild asphyxia: Mild asphyxia is defined as an Apgar score of ≤7 for 1 min or ≤7 for 5 min at birth, with umbilical artery blood pH<7.2.[26]

Severe asphyxia: Severe asphyxia is defined as an Apgar score of ≤3 for 1 min or ≤5 for 5 min at birth, with umbilical artery blood pH<7.0.[26]

Low Apgar score: An Apgar score of ≤7 for 1 or 5 min without umbilical artery blood gas results is defined as a low Apgar score.[26]

Neonatal acidosis: A pH of <7.2 and/or base excess of <−12 mmol/L based on umbilical artery blood gas analysis is defined as neonatal acidosis.[27]

Bronchopulmonary dysplasia (BPD): According to the 2001 NICHD criteria, for infants born at a GA of <32 weeks, BPD is defined as having required supplemental oxygen (>21%) for at least the first 28 postnatal days and severity is evaluated at a postmenstrual age of 36 weeks or at discharge, whichever occurs first. For infants born at a GA of ≥32 weeks, BPD is defined as having required supplemental oxygen (>21%) for at least the first 28 postnatal days and severity is evaluated at a postnatal age of 56 days or at discharge, whichever occurs first. The severity is classified as follows: mild, no oxygen use; moderate, need for oxygen and a fraction of inspiration $O_2$ ($FiO_2$) of <30%; and severe, $FiO_2$ of ≥30% or the need for continuous positive airway pressure or mechanical ventilation.[28 29]

Persistent pulmonary hypertension of the newborn (PPHN): PPHN is diagnosed using ultrasound and defined as a pulmonary artery systolic pressure of >35 mm Hg or >2/3 of the body circulation systolic pressure or as the presence of right-to-left shunting at the level of the atria or arterial conduit.[30]

Symptomatic patent ductus arteriosus (sPDA): sPDA is defined as PDA with an internal diameter of >1.5 mm, a left atrial internal diameter/aortic internal diameter ratio of ≥1.4, or a left ventricular end-diastolic internal diameter/aortic internal diameter ratio of ≥2.1, accompanied by one of the following clinical manifestations: characteristic heart murmur, hyperdynamic precordial impulse, tachycardia, bounding pulses, widened pulse pressure and worsening respiratory status.[31]

Feeding intolerance (FI): FI is defined when >50% of the last meal remains in the stomach, accompanied by vomiting and/or bloating.[32]

Acute kidney injury (AKI): AKI is classified according to neonatal AKI Kidney Diseases: Improving Global Outcomes (KDIGO) criteria.[33]

Cystic periventricular leukomalacia (cPVL): cPVL is defined as the presence of periventricular cysts on cranial ultrasound or MRI.

## Data collection

Patients will be prospectively recruited, and the recruitment phase is expected to end in 2026. Data will be collected in two parts. The data of maternal and infant information, resuscitation information and hospitalisation information will be collected on the basis of the Neonatal Resuscitation Online Registry using the Perinatal Cloud Database (https://www.perinatalcloud.com/) established by the coordinator (ZY). Each hospital will select several neonatologists as data recorders, who will be trained and assessed by the coordinating hospital before they start data collection. To ensure the accuracy of the data, we will record a video at the resuscitation site. We will standardise the use of 5G smartphones (Honor V.30 Pro mobile phones) as the video recording devices, integrating stopwatch features into the video recording functions, allowing the timing of events while simultaneously recording video (online supplemental file 3). At the resuscitation site, a mobile phone holder will be used to support the mobile phone on the top left or right of the infant radiation warming table to allow for an all-around video recording of the resuscitation process. Follow-up information will be collected by the WeChat applet 'Resuscitation Follow-up' (table 2). The applet is divided into a doctor's port and a guardian's port. The guardian can provide the results of follow-up examinations using the guardian's port on their mobile phones under the directions of the doctor. If the results are not available on the applet when the child is 2 years old, we will contact the guardian via WeChat or conduct a telephone interview.

The collected data will include the following (online supplemental file 4).

### Maternal and infant information

Infant information: name, birth hospital, hospitalisation number, sex, GA, birth weight, SGA, birth date, multiple births, congenital anomalies or hereditary syndromes and medical payment method.

Maternal information: name, age, ethnicity, mobile phone number, residential address, occupation, marital status, monthly family income, education level and medical payment method.

Antenatal information: maternal history, previous adverse pregnancy outcomes, mode of conception, antenatal care, antenatal intervention, antenatal body mass index, hypertension, diabetes, anaemia, cardiac disease, placenta praevia, placental abruptio placenta, antenatal haemorrhage, chorioamnionitis, premature rupture of membranes >18 hours, other pregnancy complications, antenatal steroid use, antenatal magnesium sulphate use, antenatal anaesthesia or analgesia, antenatal fetal monitoring anomalies, obstructed labour, emergency labour, type of labour initiation, prolonged second stage of labour, weak contractions.

Intrapartum information: mode of delivery, fetal position, amniotic fluid volume, nature of amniotic fluid, umbilical cord around the neck, umbilical cord prolapse, umbilical cord extrusion, delayed umbilical cord ligation, Apgar score (1 min, 5 min, 10 min), umbilical artery blood gas analysis and diagnosis.

### Resuscitation information

Resuscitation process: place of resuscitation; antenatal counselling; resuscitation team and division of labour; preparation of resuscitation items; warmth including the warming measure; suction or stimulation; suction device; oxygen administration, including start time, end time, duration, initial oxygen concentration and maximum oxygen concentration; use of PPV, including mode of ventilation, maximum peak inspiratory pressure, maximum positive end-expiratory pressure, start time, end time and duration; ventilation assessment; saturation of peripheral oxygen monitoring and start time; corrective ventilation steps; use of laryngeal mask airway, endotracheal tube insertion, including the number of intubations, intubation time and success of intubation; chest compression for ≥30 s, including the compression method, start time, end time and duration; electrocardiographic monitoring

**Table 2** Data collection by the WeChat applet 'Resuscitation Follow-up'

| Data | Hospitalisation period/term equivalent | Follow-up 1: corrected age, 3–6 months | Follow-up 2: corrected age, 1 year | Follow-up 3: corrected age, 2 years |
|---|---|---|---|---|
| Cranial MRI | √ | * | * | * |
| aEEG | √ | * | * | * |
| BAEP/AABR | √ | * | * | * |
| Physical examination | * | * | * | √ |
| GDS-C | | | * | √ |

√Required. *If applicable.
AABR, automatic auditory brainstem response; aEEG, amplitude-integrated electroencephalogram; BAEP, brainstem auditory-evoked potential; GDS-C, Griffiths Development Scales-Chinese; ROP, retinopathy of prematurity.

including the start time, and 100% oxygen concentration including the start time.

Resuscitation administration: umbilical vein cannulation, including the number of cannulations; epinephrine use and the number of administrations, time of administration, dose of administration and mode of administration; the type and total dose of fluid resuscitation; other interventions including the time of intervention.

Resuscitation summary: resuscitation end time, duration, resuscitation outcome (success, failure, forgo treatment), postnatal transition (transfer to neonatal ward, rooming in, transfer to another hospital, death in delivery room).

### Hospitalisation information

Treatment information: temperature on admission; therapeutic hypothermia, including the cooling method, temperature control mode and start time; postnatal glucose monitoring; and minimum blood glucose measurement.

Auxiliary examination information: echocardiography, cranial ultrasound, cranial CT, cranial MRI, amplitude-integrated electroencephalogram (aEEG), brainstem auditory evoked potentials (BAEP) or automatic auditory brainstem response (AABR) and screening for retinopathy of prematurity (ROP).

Summary of hospitalisation: duration of hospitalisation, discharge outcome (cured or improved, transfer to another hospital, death before discharge, forgo treatment), complications (pneumothorax, meconium aspiration syndrome, BPD, PPHN, sPDA, necrotising enterocolitis, FI, AKI, ROP, hypoxic-ischaemic encephalopathy, intraventricular haemorrhage, cPVL).

### Follow-up information

Follow-up examination: cranial MRI, aEEG, BAEP or AABR at the corrected age of 3~6 months, 1 year and 2 years (if applicable); physical examination; and Griffiths Development Scales-Chinese at the corrected age of 2 years (table 2).

Follow-up outcome: normal, sequelae (cerebral palsy, mental retardation, epilepsy, cognitive impairment, hearing impairment, motor retardation, neurodevelopmental delay, attention deficit, learning difficulties, visual impairment, etc), death or loss to follow-up. These data need to be confirmed jointly by the paediatric neurologist, paediatric rehabilitation physician, ophthalmologist and otolaryngologist.

## Study outcomes

The primary outcomes of this study include survival and neurodevelopmental outcomes for newborns resuscitated at birth, and the secondary outcome includes recent major illnesses.

## Data management

Each hospital will designate an attending (or above) neonatologist as a data checker, who will be trained and assessed by the coordinating hospital and will be responsible for reviewing the data from that hospital after passing the assessment. The principal investigator and data checker from each hospital form the data monitoring committee, which will be responsible for the following: for conducting quarterly data quality control meetings and providing timely feedback on the results of the checks and supervising corrective actions; for holding regular quality control and analysis meetings to assess the progress of the study and determine any deviations from the plan; for ensuring the management and operation of the online registry, video recordings, WeChat groups and WeChat applet as well as the data security; and for overall sampling quality control; recruitment of other participating hospitals; organisation of training; provision of training materials; checking, collating and analysing data and publication of the study results. If changes to the study design are required, the committee should seek approval from the Medical Ethics Committee. The Ethics Committee, independent of the data checkers or any other entity that may influence its decisions, will audit the conduct of the study annually.

To protect privacy, each hospital and its patients will have a unique identification number, and this information and data will be analysed and published in an anonymous form.

## Data integrity or withdrawal from the trial

We will apply strict quality control procedures for data collection and management to ensure data integrity. If a subject's guardian requests to withdraw during or after the trial, we will fully respect the wish, withdraw informed consent, delete the relevant information and proceed to recruit new subjects.

## Sample size estimation

The primary objective will be to provide a comprehensive description of the composite prognosis of neonates requiring PPV at birth. Because this is an observational study, sample size estimation is not necessary. We will calculate the sample size used for the logistic regression analysis of risk factors for the requirement of PPV at birth at each hospital. We expect to test 6–10 variables as potential risk factors, each with an event count of at least 10, and we will need 100 neonates resuscitated at birth.[34 35] A previous study reported that approximately 4.4% of newborns require bag-mask ventilation each year,[36 37] and assuming a 20% loss-to-follow-up rate, a minimum sample size of 2810 newborns would be required per hospital. The minimum number of neonatal deliveries in 2022 at participating hospitals was 1363, and we will prospectively collect data for 3 years so each hospital can meet the minimum sample size requirement. We expect to recruit >1500 neonates.

## Statistical analysis

Because of variations in the need for resuscitation, outcomes of neonates with different GAs and implementation of resuscitation at different hospitals, enrolled

newborns will be stratified and analysed according to the GA or hospital and standardised morbidity and survival rates will be calculated. The study will prospectively focus on enrolled neonates to investigate the prognosis as well as risk factors for neonates with different resuscitation intensities. Given the low incidence of high-intensity resuscitation, a nested case–control study design will be used to eliminate its effects. Statistical analysis will be performed using SPSS V.27.0. Data will be presented as mean (SD) or median (range) and analysed using the Student's t-test or Mann-Whitney U test. Counts will be presented as frequencies or percentages and compared using the $\chi^2$ test or Fisher's exact test. The prognosis as well as risk factors for neonates with different resuscitation intensities will be assessed by multivariable logistic regression analysis. A p value of <0.05 will be considered statistically significant.

## DISCUSSION

Neonatal resuscitation is an important topic in the field of neonatal medicine because several newborns requiring resuscitation at birth are born each year. Neonatal resuscitation almost always predicts an inability to establish spontaneous breathing,[11] and the correct implementation of neonatal resuscitation techniques can establish effective ventilation for the neonate and help him or her make a successful transition from the intrauterine to the extrauterine environment. Although guidelines for neonatal resuscitation have been updated, in China, resuscitation strategies vary widely between centres[20] and the practice and management of neonatal resuscitation are not standardised in each region. Moreover, there are very few follow-up studies on neonatal resuscitation, and the prognosis of resuscitated neonates remains unclear.

Medical registries can provide highly reliable data.[38] Many developed countries now have regional and national clinical registries aimed at improving patient health outcomes.[39] In this regard, we established the Neonatal Resuscitation Online Registry in Shenzhen and designed a prospective, multicentre, open, observational cohort study to prospectively register neonatal resuscitation cases in Shenzhen and investigate the risk factors, outcomes and resuscitation measures in actual clinical settings. Detailed documentation of the outcomes of neonates resuscitated at birth will help us gain a comprehensive understanding of the overall prognosis of this group of neonates. The long-term prognostic information will also optimise follow-up, prevent the development of severe neurodevelopmental disorders and improve the quality of life of these neonates. By exploring the risk factors for resuscitation at birth, this study is expected to show that increased monitoring of neonates with high-risk factors will help reduce the rate of resuscitation. In addition, the study will investigate resuscitation measures for neonates resuscitated at birth, identify deficient measures and provide evidence for improvement in the quality of neonatal resuscitation.

This observational study will be limited by the possibility of loss to follow-up. In order to reduce missed visits, we will establish WeChat groups, which the guardians of the subjects will join and propose that the guardians use their mobile phones to participate in follow-ups using the WeChat applet. If the guardian fails to provide follow-up results when the infant is 2 years old, we will contact the guardian via WeChat or conduct a telephone interview.

## ETHICS AND DISSEMINATION

Our protocol has been approved by the Medical Ethics Committee of Shenzhen Luohu People's Hospital, and the remaining four hospitals have signed the multicentre collaboration agreements. All guardians will be fully informed about this study. They will receive written information and sign a consent form before recruitment. The findings and results of this study will be shared among the participating hospitals and published in academic conferences and peer-reviewed paediatric journals.

**Author affiliations**
[1]Neonatology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong, China
[2]Neonatal Intensive Care Unit, Longgang District Maternity & Child Healthcare Hospital of Shenzhen City, Shenzhen, Guangdong, China
[3]Neonatology, Shenzhen People's Hospital, Shenzhen, Guangdong, China
[4]Neonatology, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, Guangdong, China
[5]Neonatology, Shenzhen Yantian District People's Hospital (Group), Shenzhen, Guangdong, China

**Acknowledgements** We thank all the hospitals and study members who participated in the Neonatal Resuscitation Online Registry Study. The authors also thank every data recorder and data checker.

**Contributors** JL and LD planned the study. LD and ZY designed the study. JL and HL provided ethical support and registered the study. HL, JH and PJ wrote the study protocol and revised the manuscript. PZ and HT performed a critical revision of the manuscript. All the authors read and approved the final version.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.



**ORCID iD**
Hanni Lin http://orcid.org/0000-0001-9428-1883

## REFERENCES


1 Perin J, Mulick A, Yeung D, *et al*. Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the sustainable development goals. *Lancet Child Adolesc Health* 2022;6:106–15.
2 Qiao J, Wang Y, Li X, *et al*. A lancet commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China. *Lancet* 2021;397:2497–536.
3 Lambert CJ, Hooper SB, Te Pas AB, *et al*. Improving newborn respiratory outcomes with a sustained inflation: a systematic narrative review of factors regulating outcome in animal and clinical studies. *Front Pediatr* 2020;8:516698.
4 Inder TE, Volpe JJ, Anderson PJ. Defining the neurologic consequences of preterm birth. *N Engl J Med* 2023;389:441–53.
5 Moshiro R, Mdoe P, Perlman JM. A global view of neonatal asphyxia and resuscitation. *Front Pediatr* 2019;7:489.
6 Okazaki K, Nakamura S, Koyano K, *et al*. Neonatal asphyxia as an inflammatory disease: reactive oxygen species and cytokines. *Front Pediatr* 2023;11:1070743.
7 Zironi I, Aicardi G. Hypoxia depresses synaptic transmission in the primary motor cortex of the infant rat-role of adenosine A1 receptors and nitric oxide. *Biomedicines* 2022;10:2875.
8 China Neonatal Resuscitation Program Task Force; Neonatal Resuscitation Subgroup, Society of Perinatal Medicine, Chinese Medical Association. China neonatal resuscitation guideline (revised in 2021). *Chin J Perinat Med* 2022;25:4–12.
9 Piao M. Following standard neonatal resuscitation procedure to ensure effective resuscitation. *Chin J Perinat Med* 2021;24:161–4.
10 Te Pas A, Roehr CC, Foglia EE, *et al*. Neonatal resuscitation research: closing the gap. *Pediatr Res* 2021;90:1117–9.
11 Foglia EE, Davis PG, Guinsburg R, *et al*. Recommended guideline for uniform reporting of neonatal resuscitation: the neonatal Utstein style. *Pediatrics* 2023;151:e2022059631.
12 Jin F, Chen Y, Liu Y-X, *et al*. Risk factors for neonatal asphyxia and establishment of a Nomogram model for predicting neonatal asphyxia in Hubei Enshi Tujia and Miao autonomous prefecture: a multicenter study. *Zhongguo Dang Dai Er Ke Za Zhi* 2023;25:697–704.
13 Foglia EE, Jensen EA, Wyckoff MH, *et al*. Survival after delivery room cardiopulmonary resuscitation: a national registry study. *Resuscitation* 2020;152:177–83.
14 Halling C, Raymond T, Brown LS, *et al*. Neonatal delivery room CPR: an analysis of the get with the guidelines®-resuscitation registry. *Resuscitation* 2021;158:236–42.
15 Handley SC, Passarella M, Raymond TT, *et al*. Epidemiology and outcomes of infants after cardiopulmonary resuscitation in the neonatal or pediatric intensive care unit from a national registry. *Resuscitation* 2021;165:14–22.
16 Carlo WA, Goudar SS, Jehan I, *et al*. High mortality rates for very low birth weight infants in developing countries despite training. *Pediatrics* 2010;126:e1072–80.
17 Matendo R, Engmann C, Ditekemena J, *et al*. Reduced perinatal mortality following enhanced training of birth attendants in the Democratic Republic of Congo: a time-dependent effect. *BMC Med* 2011;9:93.
18 Li S-J, Feng Q, Tian X-Y, *et al*. Delivery room resuscitation and short-term outcomes of extremely Preterm and extremely low birth weight infants: a multicenter survey in North China. *Chin Med J (Engl)* 2021;134:1561–8.
19 Qian M, Yu Z-B, Chen X-H, *et al*. Clinical features of preterm infants with a birth weight less than 1 500 G undergoing different intensities of resuscitation: a multicenter retrospective analysis. *Zhongguo Dang Dai Er Ke Za Zhi* 2021;23:593–8.
20 Wang S-L, Chen C, Gu X-Y, *et al*. Delivery room resuscitation intensity and associated neonatal outcomes of 24+0-31+6 weeks' preterm infants in China: a retrospective cross-sectional study. *World J Pediatr* 2024;20:64–72.
21 Shao XM, Ye HM, Qiu XS. *Practice of Neonatology*. 5th edn. 59. Beijing: People's Medical Publishing House, 2019.
22 Zhao Z, Ding M, Hu Z, *et al*. Trajectories of length, weight, and bone mineral density among preterm infants during the first 12 months of corrected age in China. *BMC Pediatr* 2015;15:91.
23 Zhu L, Zhang R, Zhang S, *et al*. Chinese neonatal birth weight curve for different gestational age. *Zhonghua Er Ke Za Zhi* 2015;53:97–103.
24 Iliadou AN, Öberg AS, Pege J, *et al*. The Uppsala-Stockholm assisted reproductive techniques (Uppstart) study. *BMJ Open* 2019;9:e028866.
25 Obstetric Subgroup, Society of Obstetrics and Gynecology, Chinese Medical Association; Society of Perinatal Medicine, Chinese Medical Association.Guideline of normal birth. *Zhonghua Fu Chan Ke Za Zhi* 2020;55:361–70.
26 Neonatal Resuscitation Subgroup, Society of Perinatal Medicine, Chinese Medical Association. Expert consensus on the diagnosis of neonatal asphyxia. *Chin J Perinat Med* 2016;19:3–6.
27 Wang Q, Piao M, Han T, *et al*. Umbilical arterial blood pH: correlation with Apgar score, relevant perinatal factors and effects on short-term neonatal outcomes. *Chin J Perinat Med* 2020;23:415–9.
28 Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2001;163:1723–9.
29 Lu Y, Kang W, Yan H, *et al*. A study on the clinical application of different diagnostic criteria for bronchopulmonary dysplasia. *Chin J Neonatol* 2022;37:510–4.
30 Neonatology Group, Chinese Pediatric Society, Chinese Medical Association; Editorial Board, Chinese Journal of Paediatrics.Experts consensus on the management of neonatal pulmonary hypertension. *Chin J Pediatr* 2017;55:163–8.
31 Evans P, O'Reilly D, Flyer JN, *et al*. Indomethacin for symptomatic patent ductus arteriosus in preterm infants. *Cochrane Database Syst Rev* 2021;1:CD013133.
32 Moore TA, Wilson ME. Feeding intolerance: a concept analysis. *Adv Neonatal Care* 2011;11:149–54.
33 Starr MC, Charlton JR, Guillet R, *et al*. Advances in neonatal acute kidney injury. *Pediatrics* 2021;148:e2021051220.
34 Pavlou M, Ambler G, Seaman SR, *et al*. How to develop a more accurate risk prediction model when there are few events. *BMJ* 2015;351:h3868.
35 Austin PC, Allignol A, Fine JP. The number of primary events per variable affects estimation of the subdistribution hazard competing risks model. *J Clin Epidemiol* 2017;83:75–84.
36 Kc A, Peven K, Ameen S, *et al*. Neonatal resuscitation: EN-BIRTH multi-country validation study. *BMC Pregnancy Childbirth* 2021;21:235.
37 Lee AC, Cousens S, Wall SN, *et al*. Neonatal resuscitation and immediate newborn assessment and stimulation for the prevention of neonatal deaths: a systematic review, meta-analysis and Delphi estimation of mortality effect. *BMC Public Health* 2011;11:S12.
38 Pop B, Fetica B, Blaga ML, *et al*. The role of medical registries, potential applications and limitations. *Med Pharm Rep* 2019;92:7–14.
39 Hoque DME, Kumari V, Ruseckaite R, *et al*. Impact of clinical registries on quality of patient care and health outcomes: protocol for a systematic review. *BMJ Open* 2016;6:e010654.

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 1

# Standard Protocol Items for Observational Studies (SPIROS)

**Table 1:** Checklist of preliminary items

| Section and topic | Description / sub-categories | Addressed on page number |
|---|---|---|
| **i) General Information** | | |
| Title | Descriptive title identifying study design | page 1 |
| Protocol version | Version or amendment number and date and summary of changes | Text headers |
| Protocol summary | Brief summary of protocol research | pages 3-4 |
| Sponsor and partner institute name | Name of sponsor and participating institutes (if applicable) | NA |
| Investigators name | Name of principal and co investigators | pages 1-2 |
| Affiliation of investigators | Affiliated institutions of investigators | pages 1-2 and 25 |
| Principal researcher contact detail | Name, email address, affiliation of Principal researcher for correspondence. | pages 1-2 |
| Table of content | Table of content | Table 1 and Table 2 |
| Page number | Page number on each page of protocol | Pages 5-20 |
| List of Abbreviations | A detailed List of all abbreviations used in protocol with full form. | NA |
| **ii) Introduction** | | |
| Background of study | Scientific background of study | Pages 5-6 |
| Review of prior research | Summary of all previous relevant research | Pages 5-6 |
| Rationale of study | Justification for conducting the study | Page 6 |
| Aim | Broader aims and specific objectives of the study | Page 7 |
| Objective of study | Primary and secondry objectives of study | Page 7 |
| Prespecified hypothesis | Prespecified null or alternative hypothesis | NA |

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 1

| | | |
|---|---|---|
| **iii) Methods** | | |
| Study design | Description of type/design of study | Page 7 |
| Study setting | Description of setting, locations, relevant dates, including periods of recruitment/survey, exposure, follow-up, and data collection.<br><br>Schedule of study procedure – Figure or table | Pages 7-16<br><br>supplementary file 2 |
| Sample size | Estimated number, calculation and assumptions<br><br>Power calculation | Pages 17-18<br><br>Pages 17-18 |
| Sampling procedure | Description of sampling strategy to ensure representativeness and control of potential bias | Pages 12-13 and 16-17 |
| Participants | **Cohort study**—eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.<br><br>For matched studies, give matching criteria and number of exposed and unexposed<br><br>**Case-control study**—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls<br><br>For matched studies, give matching criteria and the number of controls per case<br><br>**Cross-sectional study**—Give the eligibility criteria, and the sources and methods of selection of participants | Pages 9 and 12-13<br><br>NA |
| Variables | ● All outcomes<br>● Exposures- definition of exposure of interest<br>● Predictors<br>● Potential confounders | Pages 13 -16 |

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 1

| | | |
|---|---|---|
| | ● Effect modifiers | |
| Data Sources/Measurement | ● For each variable of interest, give sources of data and details of methods of assessment (measurement).<br>● Describe comparability of assessment methods if there is more than one group<br>● Data collection points table<br>● Blinding procedure | Pages 12-17<br>NA<br>Table 2<br>NA |
| Bias | Describe any efforts to address potential sources of bias<br>More specifically-<br>● Information bias<br>● Selection Bias<br>● Control for confounding | Pages 12-13 and 16-17 |
| Statistical analysis plan | ● Method of primary / secondary outcomes and additional analysis<br>● Handling of missing data<br>● Post-hoc analysis | Page 18<br>NA<br>NA |
| Handling of withdrawals and lost to follow up | Describe the procedures to be followed when a participant ceases participation in the study prematurely or is lost to follow up | Page 17 |
| Replacements | Provide information on whether or not participants who discontinue the study will be replaced via additional recruitment to maintain the required sample size. | Page 17 |
| Outcome | Define and describe all primary and secondary outcome or lost to follow up | Pages 16 |
| Database management | Detail plan of database management including:<br>● Data collection (electronic or paper based) | <br>Pages 12-16 |

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 1

| | | |
|---|---|---|
| | ● Source data<br>● Data entry<br>● Data editing<br>● Coding<br>● Data storage<br>● Record retention<br>● Data confidentiality | Pages 12-16<br>Page 12-13<br>Page 12-13<br>Page 12-13<br>Page 12-13<br>Page 12-13<br>Page 17 |
| Validation of instrument | Reliability / validity of instrument or plan to establish validation | Pages 12-13 and 16-17 |
| Follow up | Plan of follow up and addressing lost to follow up | Page 12-13 |
| Quality control | Method of quality control<br>Monitoring (internal and external)<br>Training of surveyors | Pages 16-17<br>Pages 16-17<br>Page 7, 12-13 and 16-17 |
| Quality assurance | Plan of quality assurance | Pages 16-17 |
| Expected outcome /results | A brief description of expected outcome or results | Pages 3-4 and 19 |
| **iv) Ethical consideration** | | |
| Ethical approval | Weather it has been obtained and name of ethical committees. If approval not sought, Reason | Pages 4 and 20 |
| Agreement and consent | Method of taking consent. Reason if consent not sought | Page 9 |
| Risk / Harm to participants | Any potential risk or harm to study participants | NA |
| Adverse event and Severe adverse event reporting | Outline how Adverse Event and Severe adverse event information will be collected. | NA |
| **v) Reporting and dissemination** | | |

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 1

| | | |
|---|---|---|
| Protocol amendments | Methods of communicating to investigators/ IRBs and documenting | Pages 16-17 |
| Dissemination | How results will be disseminated to participants, practitioners, public | Pages 8 and 20 |
| Publication Plan | Who has right to publish; restrictions; authorship guidelines<br>Open Access | Pages 17 and 20<br>Page 26 |
| Reporting of early stopping | Dissemination of results if trial is stopped early (for any reason) | NA |
| **vi) Others** | | |
| Limitations | Limitations of proposed study, including risk of bias | Page 4 |
| Strength of study | Highlight strengths of proposed study | Page 4 |
| References | List of references cited in protocol | Pages 20-24 |
| Data collection forms | Summary table of all forms used for data collection at each point of study | Table 2 |
| Informed consent forms | Sample of informed consent form, translated into local language | supplementary file 5 |
| Funding | Source of funding and the role of the funders for the present study | Page 25 |
| Acknowledgement for protocol development | Acknowledgement of persons involved in protocol preparation | Page 25 |
| Data sharing policy | To describe how data will be made available in public domain. | Page 20 |
| Contributions of authors to protocol | Listed authors should have participated sufficiently in prepartion of protocol with details of their contribution. | Page 25 |
| Trial registry | For observational studies also registered as trial | Page 4 |
| Annexures | Data collection form /instruments<br>Informed consent form<br>Standard operating procedures (SOPs)<br>Detailed Statistical analysis plan (SAP) | supplementary file 3<br>supplementary file 5<br>supplementary file 2<br>Page 18 |

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 2

# Flowchart of the research process for Neonatal resuscitation Online Registry in Shenzhen



Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study
Supplementary File 3

# The process of "recording video with stopwatch using a Honor V30 pro mobile phone"

When recording video with a Honor V30 pro mobile phone with a stopwatch, start the following steps:

Step 1: Open the camera of Honor V30 pro mobile phone to enter the interface.




Step 2: click on the video recording, and then click on the settings icon in the upper right corner.

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 3




Step 3:Open “Watermark” and “Record Geo Location Information” to complete the Huawei mobile phone video recording time settings.

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 3




Step 4: Start recording video.

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 4

# Registry variables for Neonatal Resuscitation Online Registry in Shenzhen

## Maternal and infant information

**Infant information**

Name: _____ Birth hospital: _____

Hospitalization number: _____ Sex: Male /Female /Hermaphroditism

Gestational age (GA): _____ Birth weight: _____ (g)

Length:_____ (cm) Head circumference:_____ (cm)

Small for gestational age (SGA): Yes /No Birth date: _____ (select)

Birth at 0:00-8:00: Yes /No Weekdays /Weekends or legal holidays

Multiple births: Yes /No Congenital anomalies or hereditary syndromes: Yes /No

Medical payment methods: Medicare /Commercial Insurance /Out-of-pocket payment

**Maternal information**

Name: _____ Age: _____ (y)

Ethnicity: _____ Mobile phone number: _____

Residential address: _____ Occupation: Yes_____ (select) /No

Marital status: Married /Unmarried /Divorced /Widowed

Monthly family income (RMB): ＜1000 /1000-3000 / 3000-5000 / 5000-8000 / ＞8000

Education level: Illiterate /elementary school /junior high school /middle school /high school /college /university and above

Medical payment methods: Medicare /commercial Insurance /out-of-pocket payment

**Antenatal information**

Maternal history: G_____ (select) P_____ (select)

previous adverse pregnancy outcomes: Yes /No

Mode of conception: Natural conception /Assisted Reproductive Technology (ART)

Antenatal care: Regular /Irregular /No /Unknown

Antenatal intervention: Yes /No

Antenatal body mass index (BMI): Low weight /normal weight / overweight /obesity

Hypertension: Yes /No

Diabetes: Yes /No

Anaemia: Yes /No

Cardiac disease: Yes /No

Placenta praevia: Yes /No

Placental abruptio placenta: Yes /No

Antenatal haemorrhage: Yes /No

Chorioamnionitis: Yes /No

Premature rupture of membranes >18h: Yes /No

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 4

Other pregnancy complications: Yes_____ /No

Antenatal steroid: Full course /Exposure /No

Antenatal magnesium sulphate: Yes /No

Antenatal anaesthesia or analgesia: Yes /No

Antenatal foetal monitoring anomalies: Yes /No

Obstructed labour: Yes /No

Emergency labour: Yes /No

Type of labour initiation: Spontaneous /Catalysis

Prolonged second stage of labour: Yes /No

Weak contractions: Yes /No

**Intrapartum information**

Mode of delivery: Vaginal delivery /Forceps delivery /Fetal head extraction /Emergency caesarean section /Elective caesarean section /Cesarean section after trial of labour

Fetal position: cephalic /breech /transverse /unknown

Amniotic fluid volume: Normal /Insufficient /Excessive

Nature of amniotic fluid: Clear /I° Faecal stained /II° Faecal stained /III° Faecal stained /Others _____

Umbilical cord around the neck: No /Yes

Umbilical cord prolapse: No /Yes

Umbilical cord extrusion: No /Yes

Delayed umbilical cord ligation: No /Yes _____ (s)

Apgar Score

1min Total score _____ (select)

Skin colour of body and extremities _____ (select) Respiration _____ (select)

Heart rate _____ (select) Muscle tone _____ (select) Reflexes _____ (select)

5min Total score _____(select)

Skin colour of body and extremities _____ (select) Respiration _____ (select)

Heart rate _____ (select) Muscle tone _____ (select) Reflexes _____ (select)

10min Total score _____ (select)

Skin colour of body and extremities _____ (select) Respiration _____ (select)

Heart rate _____ (select) Muscle tone _____ (select) Reflexes _____ (select)

Umbilical artery blood gas analysis (UABGA): No /Yes

PH _____ BE _____ mmol/L

Diagnosis: No /Mild Asphyxia /Severe Asphyxia /Low Apgar Score /Neonatal Acidosis

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 4

# Resuscitation information

**Resuscitation process**

Place of resuscitation: Delivery room /Operating theatre /Others _____

Antenatal counselling: Yes /No

Resuscitation team (numbers): _____ (select)

Resuscitation participants: Midwife /Obstetrician /Anesthesiologis /Chief neonatologist /Associate chief neonatologist / Neonatologist attending /Neonatologist resident /Neonatology nurse (multiple choices allowed)

Division of labour: Yes /No

Title of resuscitation team leader: Chief physician /Associate chiefphysician /Attending Physician /Resident /Chief nurse /Co-chief nurse /Supervisor nurse /Senior nurse /Nurse

Working experience of resuscitation team leader (numbers): _____ (select)

Preparation of resuscitation items: Advance preparation /Provisional preparation

Warmth: Yes /No

Warming measure: Preheated radiant table /Preheated towel /Hat /Plastic bag or Cling film

Suction or stimulation: Yes /No

Suction device: Rubber suction bulb /Suction

Oxygen administration: Yes /No

Start time: _____ min/after birth End time: _____ min/after birth

Duration: _____ min (automatic calculation)

Initial oxygen concentration: _____% (select)

Maximum oxygen concentration: _____% (select)

Positive-pressure ventilation: Yes /No

Mode of ventilation: Resuscitation bag /T-Piece /Nasal continuous positive airway pressure (nCPAP)

Maximum peak inspiratory pressure (PIP): _____ $cmH_2O$

Maximum positive end-expiratory pressure (PEEP): _____ $cmH_2O$

Start time: _____ min/after birth End time: _____ min/after birth

Duration: _____ min (automatic calculation)

Ventilation assessment: Good chest rise and fall /Rapid increase in heart rate (multiple choices allowed)

Saturation of Peripheral Oxygen ($SPO_2$) monitoring: Yes /No

Start time: _____ min/after birth

Corrective ventilation steps: Mask adjustment and check mask tightness /Reposition airway /Suction /Open mouth /Increase ventilation pressure appropriately (multiple choices allowed)

Laryngeal mask airway: Yes /No

Start time: _____ min/after birth End time: _____ min/after birth

Duration: _____ min (automatic calculation)

Endotracheal tube insertion: Yes /No

| Number of intubations: _____ (automatic calculation) | |
|---|---|
| Intubation time (min/after birth) | Success of intubation |
| Time: _____ | Yes /No |
| Time: _____ | Yes /No |

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 4

Chest compression ≥30 seconds: Yes /No

Compression method: Thumb method /Two-finger method

Start time: _____ min/after birth End time: _____ min/after birth

Duration: _____ min (automatic calculation)

Electrocardiographic Monitoring: Yes /No Start time: _____ min/after birth

100% oxygen concentration: Yes /No Start time: _____ min/after birth

**Resuscitation administration**

Umbilical vein cannulation: Yes /No Number of cannulations: _____ min/after birth

Epinephrine: Yes /No

| Number of administrations: _____ (automatic calculation) | | |
|---|---|---|
| Time of administration (min/after birth) | Dose of administration (mg/kg) | Mode of administration |
| Time: _____ | Dose: _____ | Endotracheal tube /Umbilical vein /Peripheral vein /Others |
| Time: _____ | Dose: _____ | Endotracheal tube /Umbilical vein /Peripheral vein /Others |

Type of fluid resuscitation: Saline /Plasma /Albumin /Erythrocyte /Others _____

Total dose: _____ ml

Other interventions: Yes _____ /No Time of intervention: _____ min/after birth

**Resuscitation summary**

Resuscitation end time: _____ (select) Duration: _____ min

Resuscitation outcome: Success /Failure /Forgo treatment

Postnatal transition: Transfer to neonatal ward /Rooming in /Transfer to another hospital /Death in delivery room

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 4

# Hospitalization information

**Treatment information**

Temperature on admission (℃): _____

Therapeutic hypothermia: Yes /No

Cooling method: Whole bod /Head /Others _____

Temperature control mode: Automatic /Manual

Start time: _____ hours/after birth

Postnatal glucose monitoring: Yes /No

Minimum blood glucose measurement: _____ mmol/L

**Auxiliary examination information**

Echocardiography: Yes /No

Examination time: _____ (select) Examination result: Normal /Abnormal _____

Cranial ultrasound: Yes /No

Examination time: _____ (select) Examination result: Normal /Abnormal

Cranial computed tomography (CT): Yes /No

Examination time: _____ (select) Examination result: Normal /Abnormal

cranial magnetic resonance imaging (MRI): Yes /No

Examination time: _____ (select) Examination result: Norma /Abnormal

Amplitude-integrated electroencephalogram (aEEG): Yes /No

Examination time: _____ (select)

Examination result: Normal /Mild abnormality /Moderate to severe abnormality

Examination time: _____ (select) Examination result (points): _____

Brainstem auditory evoked potentials (BAEP) or automatic auditory brainstem response (AABR): Yes /No

Examination time: _____ (select) Examination result: Left: Passed /Failed Right: Passed /Failed

Retinopathy of Prematurity (ROP) screening: Yes /No

Examination time: _____ (select)

Examination result: Left: Normal /Abnormal Right: Normal /Abnormal

**Summary of hospitalization**

Duration of hospitalization:_____ (d)

Discharge outcome: Cured or improved /Transfer to another hospital /Death before discharge /Forgo treatment

Complication

Pneumothorax:Yes /No

Meconium aspiration syndrome (MAS): Yes /No

Bronchopulmonary dysplasia (BPD): Yes /No

Persistent pulmonary hypertention of the newborn (PPHN): Yes /No

Symptomatic patent ductus arteriosus (sPDA): Yes /No

Necrotizing enterocolitis (NEC): IA /IB /IIA /IIB /IIIA /IIIB /No

Feeding intolerance (FI): Yes /No

Acute kidney injury (AKI): Stage 0 /Stage 1 /Stage 2 /Stage 3

ROP: Yes /No

Hypoxic-ischemic encephalopathy (HIE): Mild /Moderate /Severe /No

Intraventricular haemorrhage (IVH): Class I /Class II /Class III /Class IV /No

Cystic periventricular leukomalacia (cPVL ): Yes /No

Neonatal Resuscitation Online Registry in Shenzhen: protocol for a prospective, multicentre, open, observational cohort study

Supplementary File 4

# Follow-up information

**Follow-up examination**

Cranial MRI

| Follow-up time | Result | Follow-up recommendations |
|---|---|---|
| Time_____ (select) | Normal/abnormal | Normal, no follow-up / 1 month / 2 months / 3 months / 6 months / 1 year/2 years |
| Time_____ (select) | Normal/abnormal | Normal, no follow-up / 1 month / 2 months / 3 months / 6 months / 1 year/2 years |

aEEG

| Follow-up time | Result | Follow-up recommendations |
|---|---|---|
| Time_____ (select) | Normal/mild abnormality/moderate to severe abnormality | Normal, no follow-up / 1 month / 2 months / 3 months / 6 months / 1 year/2 years |
| Time_____ (select) | Normal/mild abnormality/moderate to severe abnormality | Normal, no follow-up / 1 month / 2 months / 3 months / 6 months / 1 year/2 years |

BAEP or AABR

| Follow-up time | Result | Follow-up recommendations |
|---|---|---|
| Time_____ (select) | Left: Passed / failed<br>Right: Passed / failed | Normal, no follow-up / 1 month / 2 months / 3 months / 6 months / 1 year/2years |
| Time_____ (select) | Left: Passed / failed<br>Right: Passed / failed | Normal, no follow-up / 1 month / 2 months / 3 months / 6 months / 1 year/2years |

Physical examination

| Follow-up time | Birth weight (g) | Length (cm) | Head circumference (cm) |
|---|---|---|---|
| Time_____ (select) | | | |
| Time_____ (select) | | | |

Griffiths Development Scales-Chinese (GDS-C)

| Follow-up time | Result | Follow-up recommendations |
|---|---|---|
| Time_____ (select) | | |
| Time_____ (select) | | |

**Follow-up outcome**: Normal /Sequelae /Death /Lost to follow-up

Sequelae: Cerebral palsy /Mental retardation /Epilepsy /Cognitive impairment /Hearing impairment /Motor retardation /Neurodevelopmental delay /Attention deficit /Learning difficulties /Visual impairment /Others